These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3059931)

  • 1. Interactions between mesolimbic dopamine neurons, cholecystokinin, and neurotensin: evidence using in vivo voltammetry.
    Phillips AG; Blaha CD; Fibiger HC; Lane RF
    Ann N Y Acad Sci; 1988; 537():347-61. PubMed ID: 3059931
    [No Abstract]   [Full Text] [Related]  

  • 2. Modulation of mesolimbic dopaminergic behaviors by cholecystokinin.
    Crawley JN
    Ann N Y Acad Sci; 1988; 537():380-96. PubMed ID: 3059933
    [No Abstract]   [Full Text] [Related]  

  • 3. Behavioural and biochemical consequences of persistent overstimulation of mesolimbic dopamine systems in the rat.
    Costall B; Domeney AM; Naylor RJ
    Neuropharmacology; 1982 Apr; 21(4):327-35. PubMed ID: 7201088
    [No Abstract]   [Full Text] [Related]  

  • 4. Behavioral evidence for differential neuropeptide modulation of the mesolimbic dopamine system.
    Kelley AE; Cador M
    Ann N Y Acad Sci; 1988; 537():415-34. PubMed ID: 2462397
    [No Abstract]   [Full Text] [Related]  

  • 5. Interactions between neuropeptides and dopamine neurons in the ventromedial mesencephalon.
    Kalivas PW
    Neurosci Biobehav Rev; 1985; 9(4):573-87. PubMed ID: 2417173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurotensin and cholecystokinin microinjected into the ventral tegmental area modulate microdialysate concentrations of dopamine and metabolites in the posterior nucleus accumbens.
    Laitinen K; Crawley JN; Mefford IN; De Witte P
    Brain Res; 1990 Jul; 523(2):342-6. PubMed ID: 1698106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurotensin and the mesocorticolimbic dopamine system.
    Bissette G; Nemeroff CB
    Ann N Y Acad Sci; 1988; 537():397-404. PubMed ID: 2849357
    [No Abstract]   [Full Text] [Related]  

  • 8. Balance of glutamate and dopamine in the nucleus accumbens modulates self-stimulation behavior after injection of cholecystokinin and neurotensin in the rat brain.
    Heidbreder C; Gewiss M; De Mot B; Mertens I; De Witte P
    Peptides; 1992; 13(3):441-9. PubMed ID: 1523160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opposite effects of mesencephalic microinjections of cholecystokinin octapeptide and neurotensin-(1-13) on brain stimulation reward.
    Rompré PP; Boye SM
    Eur J Pharmacol; 1993 Mar; 232(2-3):299-303. PubMed ID: 8467866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioral evidence for cholecystokinin modulation of dopamine in the mesolimbic pathway.
    Crawley JH
    Prog Clin Biol Res; 1985; 192():131-8. PubMed ID: 4080706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholecystokinin, dopamine, and schizophrenia: recent progress and current problems.
    Wang RY
    Ann N Y Acad Sci; 1988; 537():362-79. PubMed ID: 3059932
    [No Abstract]   [Full Text] [Related]  

  • 12. Behavioral evidence for the involvement of endogenous opioids in the interaction between cholecystokinin and brain dopamine systems.
    Király I; Van Ree JM
    Neurosci Lett; 1987 Mar; 74(3):343-7. PubMed ID: 3561887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The functional output of the mesolimbic dopamine system.
    Koob GF; Swerdlow NR
    Ann N Y Acad Sci; 1988; 537():216-27. PubMed ID: 3059925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo electrochemical analysis of cholecystokinin-induced inhibition of dopamine release in the nucleus accumbens.
    Lane RF; Blaha CD; Phillips AG
    Brain Res; 1986 Nov; 397(1):200-4. PubMed ID: 3801862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioral effects of intraaccumbens transplants in rats with lesions of the mesocorticolimbic dopamine system.
    Choulli K; Herman JP; Abrous N; Le Moal M
    Ann N Y Acad Sci; 1987; 495():497-509. PubMed ID: 3474956
    [No Abstract]   [Full Text] [Related]  

  • 16. Mesolimbic dopamine mediates gastric mucosal protection by central neurotensin.
    Xing LP; Balaban C; Seaton J; Washington J; Kauffman G
    Am J Physiol; 1991 Jan; 260(1 Pt 1):G34-8. PubMed ID: 1899007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substance P modulation of the mesolimbic dopamine system.
    Kalivas P
    Prog Clin Biol Res; 1985; 192():403-8. PubMed ID: 2417255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurotensin and cholecystokinin octapeptide control synergistically dopamine release and dopamine D2 receptor affinity in rat neostriatum.
    Tanganelli S; Li XM; Ferraro L; Von Euler G; O'Connor WT; Bianchi C; Beani L; Fuxe K
    Eur J Pharmacol; 1993 Jan; 230(2):159-66. PubMed ID: 8422898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesolimbic and mesocortical dopaminergic neurons are necessary for normal exploratory behavior in rats.
    Fink JS; Smith GP
    Neurosci Lett; 1980 Apr; 17(1-2):61-5. PubMed ID: 6820483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of dopamine on limbic inputs to the nucleus accumbens.
    Mogenson GJ; Yang CR; Yim CY
    Ann N Y Acad Sci; 1988; 537():86-100. PubMed ID: 3059937
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.